dinoprost and Kidney-Failure--Chronic

dinoprost has been researched along with Kidney-Failure--Chronic* in 18 studies

Trials

6 trial(s) available for dinoprost and Kidney-Failure--Chronic

ArticleYear
Effect of omega-3 fatty acids on plasma level of 8-isoprostane in kidney transplant patients.
    Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 2011, Volume: 21, Issue:2

    It has been shown previously that the serum level of F2-isoprostanes acts as an indicator of oxidative stress, which is a risk factor for vascular disease especially in end-stage renal disease. It is not known whether n-3 polyunsaturated fatty acids can decrease oxidative stress in renal recipient patients.. In this single blind, randomized, placebo-controlled study, the effect of 3 and 6 months of fish oil administration on 8-isoprostane levels in renal transplant recipients was evaluated.. Twenty-two renal transplant patients who fulfilled inclusion and exclusion criteria randomly received either fish oil dietary supplementation, 6 g/day (720 mg of DHA and 1,080 mg of EPA) or placebo for 6 months.. Serum 8-isoprostane concentration was measured as markers of oxidative stress.. A significant decrease in 8-isoprostane levels was observed only in the placebo group after transplantation compared to baseline (P < 0.05). However, the group receiving fish oil had a significantly lower cholesterol level than that of the placebo group (P < 0.05).. On the basis of our results, omega-3 fatty acids supplementation decreased the beneficial effects of kidney transplantation on oxidative stress.

    Topics: Adult; Dinoprost; F2-Isoprostanes; Fatty Acids, Omega-3; Female; Fish Oils; Humans; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Oxidative Stress; Risk Factors; Single-Blind Method; Young Adult

2011
Atorvastatin attenuates oxidative stress in patients with chronic kidney disease.
    Medical science monitor : international medical journal of experimental and clinical research, 2010, Volume: 16, Issue:3

    Topics: Adult; Atorvastatin; Dinoprost; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoprostanes; Kidney Failure, Chronic; Male; Oxidative Stress; Placebos; Pyrroles

2010
N-acetylcysteine for the management of anemia and oxidative stress in hemodialysis patients.
    Nephron. Clinical practice, 2010, Volume: 116, Issue:3

    To explore the efficacy of oral N-acetylcysteine (NAC) supplementation for anemia and oxidative stress in hemodialysis (HD) patients.. Of the eligible patients (n = 325) in an outpatient HD unit, 49 received NAC 200 mg orally thrice a day during the first 3 months, while the other 276 patients not receiving NAC were observed.. During the 4-month study, 11 patients receiving NAC withdrew but had no severe adverse effects, while 49 patients not receiving NAC had negative confounding events. Thus only the data of the remaining patients, 38 taking NAC and 227 not taking NAC, were analyzed for efficacy. The demographic and laboratory data of both groups were similar at baseline. When the erythropoietin dosage was stable throughout, only the NAC group had a significant increase in hematocrit, accompanied with a decrease in plasma levels of 8-isoprostane and oxidized low-density lipoprotein. Analyzed as a nested case-control study, NAC supplementation was also found to be a significant predictor of positive outcomes in uremic anemia.. Oral NAC supplementation may be a promising therapy for uremic anemia and oxidative stress in HD patients.

    Topics: Acetylcysteine; Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antioxidants; Case-Control Studies; Chlorides; Dinoprost; Erythropoietin; Female; Ferric Compounds; Hematocrit; Humans; Kidney Failure, Chronic; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress; Recombinant Proteins; Renal Dialysis

2010
Antioxidant therapy does not ameliorate oxidative stress and inflammation in patients with end-stage renal disease.
    Journal of the National Medical Association, 2009, Volume: 101, Issue:4

    Oxidative stress and inflammation are common manifestations and major mediators of cardiovascular and many other complications of end-stage renal disease (ESRD). Oxidative stress and inflammation are intimately interrelated as each can cause the other. The present study tested the hypothesis that antioxidant therapy may alleviate oxidative stress and improve inflammation in ESRD patients. We studied 37 hemodialysis patients, of whom 20 were treated daily with a combination of vitamin E, 800 lU; vitamin C, 250 mg; vitamin B6, 100 mg; vitamin B12, 250 microg; and folic acid, 10 mg; whereas 17 patients were given placebo for 8 weeks. Predialysis levels of f-2 isoprostane and protein carbonyl (markers of oxidative stress), C-reactive protein (CRP) and IL6 (markers/ mediators of inflammation) were measured prior to and at 4 and 8 weeks after the onset of therapy. Kt/V, predialysis and postdialysis blood pressure, blood hemoglobin, erythropoietin requirement, plasma ferritin and transferrin saturation, and nutritional indexes were similar among the 2 groups at baseline and remained virtually unchanged throughout the study period. Likewise, plasma f-2 isoprostane, protein carbonyl, CRP, and IL-6 levels remained unchanged and were unaffected by antioxidant administration. In conclusion, the addition of a potent antioxidant cocktail to conventional vitamin supplements had no effect on severity of ESRD-induced oxidative stress, inflammation, hypertension, anemia, or nutritional disorders in hemodialysis patients. Thus, high doses of vitamins beyond the routinely prescribed vitamin supplements do not appear to be indicated in this population.

    Topics: Anemia; Antioxidants; C-Reactive Protein; Dinoprost; Double-Blind Method; Female; Humans; Hypertension; Inflammation; Interleukin-6; Kidney Failure, Chronic; Male; Middle Aged; Oxidative Stress; Protein Carbonylation; Renal Dialysis; Vitamins

2009
Effects of low- and high-flux dialyzers on oxidative stress and insulin resistance.
    Blood purification, 2008, Volume: 26, Issue:2

    Cardiovascular disease (CVD) is the leading cause of mortality in patients with end-stage renal disease (ESRD). The cornerstone of high CVD incidence in ESRD patients is endothelial dysfunction which results from inflammation, oxidative stress and insulin resistance. Although various modalities of hemodialysis (HD) have been presumed to exert different effects on oxidative stress and insulin resistance, solid evidence is still lacking.. 40 ESRD patients undergoing HD were prospectively enrolled and divided randomly into two groups. Patients in each group received either F8 HPS (low-flux) (Group A) or FX80 (high-flux) (Group B) as HD dialyzers for 2 consecutive months. Diet pattern and medications were kept as usual in both groups to avoid considerable blood glucose change during study period. Blood samples were taken at the start and end of the study.. A total of 38 patients (18 and 20 for Groups A and B, respectively) completed the study. Within each group, there was no change in adiponectin, plasma 8-iso-prostaglandin F(2)(alpha), high-sensitivity C-reactive protein, blood glucose and insulin after 2 months of treatment except a significant change of HOMA(IR) (p = 0.02) in high-flux group. The significant change of HOMA(IR) between the two groups (p = 0.017) mainly results from the parallel change of insulin between the two groups (p = 0.03).. For patients receiving HD, the high-flux dialyzer with synthetic polysulfone membranes fails to provide a better anti-inflammatory or antioxidative effect than the low-flux dialyzer; however, the high-flux dialyzer does significantly improve insulin resistance in this short-term study. This result implies that the high-flux dialyzer might provide better cardiovascular protection than the low-flux dialyzer. Therefore, the low-flux dialyzer might be considered for patients who only need short-term HD therapy. Regarding patients under long-term maintenance HD therapy, a high-flux dialyzer might be the choice of dialyzer.

    Topics: Adiponectin; Aged; Cardiovascular Diseases; Dinoprost; Endothelial Cells; Endothelium, Vascular; Female; Humans; Insulin Resistance; Kidney Failure, Chronic; Male; Membranes, Artificial; Middle Aged; Oxidative Stress; Renal Dialysis

2008
Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 45, Issue:5

    Hemodialysis patients have uremic dyslipidemia, represented by elevated serum intermediate-density lipoprotein cholesterol (IDL-C) levels, and an increased cardiovascular mortality rate. This study was performed to determine the low-dose effects of the angiotensin II receptor blocker losartan and the angiotensin-converting enzyme inhibitor trandolapril on pulse wave velocity (PWV), which predicts cardiovascular morbidity and mortality in hemodialysis patients.. Serum lipid levels and PWV were monitored for 12 months in 64 hemodialysis patients who were administered low doses of losartan or trandolapril or a placebo.. At the start of the study, there were no differences in patient characteristics among the 3 groups. PWV tended to increase in the placebo group during the 12-month study period, but decreased significantly in the losartan and trandolapril groups, and decreases in PWV were similar in the losartan and trandolapril groups. There were no changes in blood pressure, hematocrit, erythropoietin dose, ankle-brachial index, serum lipid levels, serum 8-isoprostane levels, or serum C-reactive protein levels during the 12-month study period, but there was an increase in serum triglyceride levels in the losartan group and a decrease in serum IDL-C levels in the losartan and trandolapril groups.. In hemodialysis patients, trandolapril is as effective as losartan in decreasing PWV independent of its depressor effect and in suppressing elevated IDL-C levels. Long-term blockade of the renin-angiotensin system may have a beneficial effect on the acceleration of atherosclerosis and uremic dyslipidemia.

    Topics: Aged; Anemia; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Comorbidity; Dinoprost; Drug Therapy, Combination; Erythropoietin; Female; Follow-Up Studies; Hematocrit; Humans; Hyperlipidemias; Indoles; Kidney Failure, Chronic; Lipids; Lipoproteins; Lipoproteins, LDL; Losartan; Male; Middle Aged; Prospective Studies; Renal Dialysis; Treatment Outcome; Vascular Resistance

2005

Other Studies

12 other study(ies) available for dinoprost and Kidney-Failure--Chronic

ArticleYear
Investigation of the Oxidative Stress and DIO1 Expression in CRF Patients Accompanied With and Without Euthyroid Sick Syndrome.
    Kidney & blood pressure research, 2018, Volume: 43, Issue:3

    Chronic renal failure (CRF) is often accompanied by increased oxidative stress and euthyroid sick syndrome (ESS). The cause of ESS is unknown, and it is unknown whether there exists a link between oxidant stress and ESS in CRF patients. Therefore, we aim to investigate oxidative stress and type 1 deiodinase (DIO1) expression, which plays the key role in the ESS in CRF patients.. In-patients with CRF were divided into the two group: Group 1 is ESS patients consisting of 60 patients with low free triiodothyronine (FT3) and Group 2 consisting of 60 patients with normal FT3. Group 3 consisted of 60 healthy volunteers recruited as controls. The baseline clinical parameters of patients were evaluated with standard routine methods in a clinical laboratory. Serum levels of 8-isoprostane and DIO1 were measured by enzyme-linked immunosorbent assay (ELISA). Multiple regression analysis was used to analyze the relationship between oxidative stress, DIO1 and FT3.. The concentrations of serum 8-Isoprostane in Group 1 and Group 2 were substantially higher than that of Group 3 (p< 0.05), however there was no significant difference between Group 1 and Group 2 (p=0.516). The serum DIO1 level was higher in Group 2 than in Group 1 and Group 3 (p< 0.001). Multivariate linear regression analysis revealed that the DIO1 concentration and FT3 level were not associated with the concentration of serum 8-Isoprostane.. CRF patients showed elevated oxidative stress. The CRF patients without ESS showed higher expression of DIO1 than patients with ESS and the control group. The concentration of serum 8-Isoprostane was not correlated with FT3 and DIO1 levels.

    Topics: Aged; Case-Control Studies; Dinoprost; DNA-Binding Proteins; Euthyroid Sick Syndromes; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Oxidative Stress; Triiodothyronine

2018
Increase in oxidative stress but not in antioxidant capacity with advancing stages of chronic kidney disease.
    American journal of nephrology, 2008, Volume: 28, Issue:3

    Increased oxidative stress in chronic kidney disease (CKD) was suggested to be both a cause and an effect of renal injury. However, the evolution of oxidant stress from early stages of renal function decline is not fully clear. This study aimed to determine the oxidant-antioxidant balance across the whole range of renal function.. A total of 116 patients with CKD (85 predialysis patients divided into groups according to CKD stage, and 31 patients with end-stage renal disease (ESRD) on hemodialysis treatment), as well as 29 healthy subjects were evaluated. Plasma levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP), a valid marker of oxidant stress, as well as total antioxidant capacity (TAC) and serum levels of vitamin E were measured in all participants.. Plasma 15-F(2t)-IsoP levels were higher in predialysis and ESRD patients compared to healthy subjects and were progressively increasing with advancing CKD stages (p < 0.001). In contrast, plasma TAC was similar between healthy subjects and predialysis patients, and presented a small reduction in ESRD patients (p < 0.001). Vitamin E levels were higher in healthy subjects compared to any other group (p < 0.001) and slightly higher in ESRD patients compared to predialysis patients (p < 0.01), but did not differ significantly between the groups of predialysis patients. Plasma 15-F(2t)-IsoP levels were inversely correlated with estimated glomerular filtration rate in predialysis patients (r = -0.65, p < 0.001).. This study shows that 15-F(2t)-IsoP levels increase progressively with advancing CKD stages, whereas TAC and vitamin E levels remain rather stable with the loss of renal function and change only in patients with ESRD.

    Topics: Adult; Aged; alpha-Tocopherol; Antioxidants; Dinoprost; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Oxidative Stress

2008
Oxidative stress and inflammation in long-term renal transplanted hypertensives.
    Clinical nephrology, 2006, Volume: 66, Issue:1

    Several studies have shown that chronic renal failure (CRF) is characterized by "accelerated atherosclerosis". More recent studies emphasize that inflammation and oxidative stress play a central role in atherosclerosis, and it is well-established that C-reactive protein (CRP) is a cardiovascular risk marker in the general population, in end-stage renal disease (ESRD) patients and in allograft recipients.. We measured the serum concentration of high sensitivity CRP, TNFalpha, 8-iso-prostaglandin F2alpha (8-iso-PGF2alpha, an in vivo oxidative stress marker) in 15 CRF patients and in 15 transplant recipients. Exclusion criteria were age < 30 and > 65 years, smoking, diabetes mellitus and history of cardiovascular diseases. Immunosuppressive therapy was not withdrawn, and antihypertensive treatment was the same for both groups. Systolic (SBP) and diastolic blood pressure (DBP), serum creatinine (sCr) and estimated glomerular filtration rate (GFR) were also evaluated. 15 healthy subjects were enrolled as controls.. The transplanted group showed significantly higher values than controls of CRP (p < 0.05), TNFalpha (p < 0.05), 8-iso-PGF2alpha (p < 0.05). The CRF group as well exhibited, in comparison with controls significantly higher concentrations of CRP (p < 0.05), TNFalpha (p < 0.05), and 8-iso-PGF2alpha (p < 0.05). SBP, DBP and sCr were not different between transplanted and CRF patients. CRP was higher in transplant recipients than in CRF patients (p < 0.05). No difference in TNFalpha levels between the 2 groups was found. 8-iso-PGF2alpha was significantly higher in CRF than in the transplanted group (p < 0.05). In this latter, 8-iso-PGF2alpha showed a positive correlation with TNFalpha (p < 0.001), sCr (p < 0.001), SBP (p < 0.05) and DBP (p < 0.05). In the same group both 8-iso-PGF2alpha and TNFalpha were negatively correlated with GFR (r = -0.873 and -0.912, respectively, p < 0.001 for both).. Our data have shown the coexistence of an increased oxidative stress and an inflammatory state in long-term renal graft recipients.

    Topics: Adult; C-Reactive Protein; Case-Control Studies; Dinoprost; Humans; Hypertension; Inflammation Mediators; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Oxidative Stress; Time Factors; Tumor Necrosis Factor-alpha

2006
Elevated plasma and urine levels of ADMA and 15(S)-8-iso-PGF2alpha in end-stage liver disease.
    Hepatology (Baltimore, Md.), 2003, Volume: 38, Issue:4

    Topics: Adult; Aged; Arginine; Dinoprost; F2-Isoprostanes; Female; Humans; Kidney Failure, Chronic; Liver Diseases; Male; Middle Aged

2003
8-iso-prostaglandin F2alpha as a useful clinical biomarker of oxidative stress in ESRD patients.
    Blood purification, 2002, Volume: 20, Issue:6

    Chronic renal failure is associated with elevated indices of oxidative stress. We tested the hypothesis that the in vivo formation of the F(2)-isoprostane (8-iso-prostaglandin PGF(2alpha)), a bioactive product of arachidonic acid peroxidation, is enhanced in end-stage renal disease (ESRD) patients receiving hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD).. Plasma samples were obtained from 35 HD patients, 30 CAPD patients and 30 age- and sex-matched healthy subjects for measurement of immunoreactive 8-iso-PGF(2alpha).. Plasma 8-iso-PGF(2alpha) levels were significantly higher (p < 0.001) in HD and CAPD patients (346.3 +/- 132.4 pg/ml; range 49.8-870) than in age-matched control subjects (150.9 +/- 61.6 pg/ml; range 33.5-235). In addition, we also found that 8-iso-PGF(2alpha) concentration was significantly (p = 0.007) higher in HD patients (389.8 +/- 148.3 pg/ml) than in CAPD patients (254.3 +/- 76.6 pg/ml). Plasma 8-iso-PGF(2alpha) concentration was linearly correlated with serum haptoglobin, C-reactive protein (CRP) and plasma MDA (r = 0.58, p = 0.003; r = 0.29, p < 0.05 and r = 0.38, p < 0.05 respectively). On the other hand, plasma 8-iso-PGF(2alpha) levels were inversely associated with serum albumin and total cholesterol (r = -0.31 and r = -0.28, respectively; p < 0.05).. We conclude that ESRD on both HD and CAPD is associated with increased formation of F(2)-isoprostanes, a correlate of enhanced lipid peroxidation. We also found that plasma 8-iso-PGF(2alpha) was casually related to some acute phase reactant proteins such as serum CRP, albumin and haptoglobin. This may provide an important biochemical link between lipid peroxidation, inflammation and accelerated atherosclerosis in the uremic milieu.

    Topics: Adult; Biomarkers; Case-Control Studies; Dinoprost; F2-Isoprostanes; Female; Humans; Kidney Failure, Chronic; Lipid Peroxidation; Male; Middle Aged; Oxidative Stress; Peritoneal Dialysis, Continuous Ambulatory; Renal Dialysis

2002
Elevated plasma F2-isoprostanes in patients on long-term hemodialysis.
    Kidney international, 2001, Volume: 59, Issue:5

    End-stage renal disease (ESRD) patients on long-term hemodialysis (HD) may be under increased oxidative stress, caused by either HD or renal failure. Plasma F2-isoprostanes have been established as an important indicator of in vivo oxidative stress.. Plasma esterified F2-isoprostanes were measured in 25 HD patients and 23 controls with normal renal function, employing gas chromatography-mass spectrometry with negative chemical ionization (GC-MS-NCI). C-reactive protein (CRP) was determined concurrently in patients and controls by enzyme-linked immunosorbent assay (ELISA). alpha-Tocopherol, retinol, albumin and creatinine were also determined.. The average total esterified F2-isoprostanes in the ESRD patients was 1.62 +/- 0.73 vs. 0.27 +/- 0.10 ng/mL in controls (P < 0.001), with no overlap between patients and controls. Plasma F2-isoprostanes in diabetic ESRD patients were similar to F2-isoprostanes in patients with other causes for renal failure. In a subset of 10 of these ESRD patients evaluated eight months after the initial measurement, plasma-esterified F2-isoprostanes were not altered by an individual dialysis session. Average plasma CRP values were also higher in HD patients (P < 0.02), but some patients had CRP values that were similar to controls. In the HD patients, total plasma F2-isoprostanes and plasma CRP were correlated (r = 0.48, P = 0.015). Plasma alpha-tocopherol did not differ between patients and controls, but plasma retinol was higher in patients (3.15 +/- 1.71 micromol/L) than in controls (1.97 +/- 0.51 micromol/L, P < 0.05).. These results are consistent with the hypothesis that oxidative stress in ESRD patients contributes to increased values of esterified plasma F2-isoprostanes, with concurrent increases in plasma CRP levels in some patients. Impaired clearance of esterified F2-isoprostanes may contribute to the elevated levels in renal failure. Plasma esterified F2-isoprostanes may be a useful indicator to evaluate effectiveness of interventions to decrease oxidative stress and associated inflammation.

    Topics: Aged; C-Reactive Protein; Case-Control Studies; Dinoprost; Esterification; F2-Isoprostanes; Female; Gas Chromatography-Mass Spectrometry; Humans; Kidney Failure, Chronic; Male; Middle Aged; Oxidative Stress; Renal Dialysis; Vitamin A; Vitamin E

2001
Plasma 8-epi PGF2 alpha levels in health and disease.
    Advances in experimental medicine and biology, 1997, Volume: 433

    Topics: Biomarkers; Diabetes Mellitus, Type 2; Dinoprost; Gas Chromatography-Mass Spectrometry; Humans; Hyperlipidemias; Kidney Failure, Chronic; Reference Values

1997
Systemic and renal production of thromboxane A2 and prostacyclin in decompensated liver disease and hepatorenal syndrome.
    Gastroenterology, 1991, Volume: 100, Issue:4

    To assess the role of altered renal and systemic production of thromboxane A2 and prostacyclin in the hepatorenal syndrome, urinary excretion of their major renal and extrarenal metabolites was measured in patients with compensated and decompensated liver disease, chronic renal failure, and hepatorenal syndrome. Urinary excretion rates of all prostanoids (renal and extrarenal) were increased in subjects with liver disease compared with normal controls. Moreover, they were considerably higher in subjects with severe hepatic decompensation but good renal function compared with those with hepatorenal syndrome. In contrast, the excretion rate of all metabolites was reduced in patients with chronic renal failure. The excretion rate of all metabolites was markedly elevated during the early stages of hepatorenal syndrome and decreased in parallel with creatinine clearance. When corrected for creatinine clearance, there was a strong correlation between prostanoid excretion and serum bilirubin in subjects with liver disease; there was no difference, however, in the excretion of renal and extrarenal prostanoids between hepatorenal syndrome and severe hepatic decompensation. It is concluded that hepatic decompensation is associated with a progressive increase in prostanoid excretion but that changes in production of prostacyclin or thromboxane A2 are unlikely to be major factors in the pathogenesis of the hepatorenal syndrome.

    Topics: Adult; Aged; Ascites; Bilirubin; Creatinine; Dinoprost; Epoprostenol; Female; Hepatorenal Syndrome; Humans; Kidney; Kidney Failure, Chronic; Liver Cirrhosis; Liver Diseases; Male; Middle Aged; Thromboxane A2; Thromboxane B2

1991
Urinary prostaglandins E2 and F2 alpha in chronic renal failure. Influence of chronic and acute changes in Na balance.
    Nephron, 1985, Volume: 40, Issue:2

    The role played by renal prostaglandins E2 (PGE2) and F2 alpha (PGF 2 alpha) in the modification of sodium homeostasis in chronic renal failure (CFR) was studied. The 24-hour urinary excretion of PGE2 and PGF2 alpha was measured before and after 5 days of a diet containing less than 20 mmol/day of sodium in 6 patients with CRF. At the end of this period, an acute sodium load (77 mmol/h of NaCl for 4 h) was administered and prostaglandins measured in hourly urine collections. In contrast to the findings previously reported in normal subjects, PGE2 and PGF2 alpha decreased with the low-sodium diet. The ratio PGE2/PGF2 alpha (reflecting the activity of the enzyme PGE2-9-ketoreductase) was greatly increased and did not change with the low-sodium diet. The acute sodium load induced an increase in urinary prostaglandins. The results suggest that prostaglandins may contribute to natriuresis in CRF, under basal conditions, after a short-term sodium depletion and in response to an acute sodium load. The changes in prostaglandin excretion in CRF could be related to decreased activity of PGE2-9-ketoreductase.

    Topics: Adult; Aged; Diet, Sodium-Restricted; Dinoprost; Dinoprostone; Homeostasis; Humans; Kidney Failure, Chronic; Male; Middle Aged; Prostaglandins E; Prostaglandins F; Sodium; Sodium Chloride; Time Factors

1985
The relationship between "zheng-syndromes" in traditional Chinese medicine and prostaglandins.
    Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 1985, Volume: 5, Issue:1

    Topics: Adult; Aged; Alprostadil; Connective Tissue Diseases; Diabetes Mellitus; Dinoprost; Factor Analysis, Statistical; Female; Humans; Kidney Failure, Chronic; Lung Diseases, Obstructive; Male; Medicine, Chinese Traditional; Medicine, East Asian Traditional; Middle Aged; Neoplasms; Prostaglandins E; Prostaglandins F

1985
Stimulation of peritoneal synthesis of vasoactive prostaglandins during peritonitis in patients on continuous ambulatory peritoneal dialysis.
    European journal of clinical investigation, 1985, Volume: 15, Issue:1

    The peritoneal generation of arachidonic acid metabolites was studied in eight patients with end-stage renal disease undergoing continuous ambulatory peritoneal dialysis (CAPD) during infection-free periods and during bacterial peritonitis. The prostacyclin metabolite 6-keto-PGF1 alpha was found to be the major prostanoid generated by human peritoneal mesothelium (1090 ng (6h)-1, SEM 86, n = 8) followed by lesser amounts of PGE2 (142 ng (6 h)-1, SEM 26, n = 8), PGF2 alpha (162 ng (6 h)-1, SEM 27, n = 8) and TXB2 (59 ng (6 h)-1, SEM 5, n = 8). During peritonitis a significant increase of all prostaglandins and TXB2 occurred (P less than 0.001). The ratio of the vasodilating prostaglandins and their metabolites (PGE2 and 6-keto-PGF1 alpha) to the vasoconstrictors and their metabolites (PGF2 alpha and TXB2) increased from 6.6 to 10.5 during peritoneal inflammation. Augmented peritoneal clearances of creatinin and urea and increased losses of proteins during peritonitis as well as the enhanced peritoneal generation of prostanoids were reduced to basal values by adequate antibiotic therapy. The present results suggest that the increased peritoneal blood flow during peritonitis, probably responsible for the observed changes of peritoneal transport properties, may be induced by a change in the ratio of vasoactive prostaglandins generated by peritoneal mesothelial cells.

    Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Dinoprost; Dinoprostone; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis; Peritoneal Dialysis, Continuous Ambulatory; Peritonitis; Prostaglandins; Prostaglandins E; Prostaglandins F; Thromboxane B2

1985
[Prostaglandin F2 alpha and renal hypertension].
    Vutreshni bolesti, 1981, Volume: 20, Issue:6

    The values of PGf2 alpha were studied in 20 renal patients with renal hypertension, with and without chronic renal insufficiency via a radioimmunologic method. A control group of 10 healthy volunteers wer used without data from arterial hypertension. Values (672.0 +/- 99.5 pg/ml), being, with statistically significant difference, increased as compared with the healthy volunteers (347.13 +/- 49.9 pg/ml) were found in renal patients with chronic renal insufficiency. With the advancement of CRI in patients with renal hypertension, PG concentration was also increased (505.5 +/- 77.6 pg/ml) but it was not significant as in the patients without CRI. The elevated values of PGF2+ alpha suggest their participation in the pathogenesis of renal hypertension.

    Topics: Adult; Chronic Disease; Dinoprost; Female; Humans; Hypertension, Renal; Kidney Failure, Chronic; Male; Prostaglandins F; Pyelonephritis

1981